Ruibo (Taizhou) Pharmaceutical Co., Ltd. announced that it will receive CNY 300,000,000 in an equity round of funding on April 8, 2024. The transaction will include participation from returning investor Zhejiang Jiuzhou Pharmaceutical Co., Ltd to retain the majority stake in the company. This has been viewed and approved by the fourth meeting of the eighth board of directors and the third meeting of the eighth board of supervisors of the Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Post-completion of the transaction, the registered capital of the company will increase from CNY 150,000,000 to CNY 175,000,000, and the capital increase premium of CNY 275,000,000 will be included in the capital reserve.